Comparison of the effects of different ways of giving Bicalutamide combined with Goserelin in the treatment of advanced prostate cancer and influence on the expression of serum PSA, VEGF and miR-34a
LI Xiunan QIN Jie ZHANG Junpeng MA Chuanyu WANG Xingli WU Dongjun CHEN Xiaochi
Department of Urology, the First Affiliated Hospital of Dalian Medical University, Liaoning Province, Dalian 116600, China
Abstract：Objective To analyze the effects of different ways of giving Bicalutamide combined with Goserelin in the treatment of advanced prostate cancer and influence on the expression of serum prostate-specific antigen (PSA), vascular endothelial growth factor (VEGF) and miRNA-34a (miR-34a). Methods From February 2015 to December 2016, 80 patients with advanced prostate cancer in the First Affiliated Hospital of Dalian Medical University were selected as research objects, and divided into study group and control group by random number table, with 40 cases in each group. The study group was treated with oral Bicarbonide and subcutaneous injection of Goserelin, when PSA< 0.2 ng/mL, stop taking these two drugs, and when PSA>4 ng/mL, continue to take these two drugs. The control group was given continuous medication. The serum PSA, VEGF, mir-34a and the incidence of urinary tract obstruction were detected and recorded before and after treatment, and the treatment effect, the incictence of adverse effects, the average treatment cost between two groups were compared. Results The serum PSA, VEGF, mir-34a and urinary obstruction of patients in the two groups after treatment for 3, 6, 9 months and 12 months were all lower than those before treatment, the differences were statistically significant (P < 0.05), and the two groups were compared, the differences were not statistically significant (P > 0.05). After treatment, the overall response rate in the study group was higher than control group, the difference was statistically significant (P < 0.05), the average treatment cost in the study group was lower than control group, the difference was statistically significant (P < 0.05), both groups had different levels of adverse reactions, but they were compared, the difference was not statistically significant (P > 0.05). Conclusion Bicalutamide combined with Goserelin intermittent and continuous administration all can improve the serum PSA, VEGF and miR-34a in patients with advanced prostate cancer, while the effect of intermittent administration is more obvious, and the effect is good.
李秀男 秦杰 张浚鹏 马传宇 王行立 吴东军 陈骁驰. 比卡鲁胺联合戈舍瑞林不同给药方式治疗晚期前列腺癌的效果比较及对血清PSA、VEGF和miR-34a表达的影响[J]. 中国医药导报, 2018, 15(6): 53-57.
LI Xiunan QIN Jie ZHANG Junpeng MA Chuanyu WANG Xingli WU Dongjun CHEN Xiaochi. Comparison of the effects of different ways of giving Bicalutamide combined with Goserelin in the treatment of advanced prostate cancer and influence on the expression of serum PSA, VEGF and miR-34a. 中国医药导报, 2018, 15(6): 53-57.
2018, Vol. 15 
京公网安备 11010502046598号